Summary
Standard immunological parameters measuring non-specific cellular immune reactivity were determined in 175 patients with different stages of gastric cancer prior to surgery and during follow-up. Several tests measuring monocyte activity were also employed. The total number of T cells and their subpopulations Ta and T29° was unchanged except depression of T29° in stage IV. The blastogenic response of lymphocytes to PHA as assessed by stimulation of protein synthesis was only depressed in stage IV. In contrast the PHA-induced lymphokine production was increased in all patients but the differences were significant for stage III and IV. Monocyte Fc receptor expression was increased in stages II-IV, while nitro blue tetrazolium reduction and antibody dependent cellular cytotoxicity of monocytes was elevated in stage IV. The number of extractable monocytes was not increased. Longitudinal studies suggested that most of the parameters normalized during follow-up. No major long-term impact of chemoimmunotherapy (5-FU+BCG) on the immune parameters was observed except a transient increase in PPD reactivity approximately 1 year after commencement of treatment. In patients with stage III gastric cancer the increased occurrence of suppressor cells (mostly monocytes) and elevated cytostatic activity of monocytes was associated with a longer survival while the increased lymphokine production and Fc receptor expression were seen in the group of patients succumbing earlier. We concluded that most of the changes in immune parameters were seen only in advanced disease and paradoxically disappeared in the course of disease. The determination of monocyte activity seems to be a sensitive indicator of immune system dearrangements in earlier stages of cancer and a useful prognostic factor in gastric cancer.
Similar content being viewed by others
References
Adkinson HF Jr, Rosenberg SA, Terry WD (1974) Early detection of lymphocyte stimulation and mixed lymphocyte interaction in man with semimicro protein synthesis assay. J Immunol 112:1426–1436
Bianco C, Patrick R, Nussenzweig V (1970) A population of lymphocyte bearing membrane receptor for antigen-antibody-complement complexes. J Exp Med 132:702–708
Braun DP, Nisius S, Hollinshead A, Harris JE (1983) Serial immune testing in surgically resected lung cancer patients. Cancer Immunol Immunother 15:114–120
Cannon GB, Dean JH, Herberman RB (1980) Association of depressed lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int J Cancer 26:9–17
Cannon GB, Dean JH, Herberman RB, Keels M, Alford C (1981) Lymphoproliferative responses to autologous tumour extracts as prognostic indicators in patients with resected breast cancer. Int J Cancer 27:131–138
Catalona WJ, Samplem WF, Chretien PB (1973) Lymphocyte reactivity in cancer patients. Correlation with tumour histology and clinical stage. Cancer 31:65–71
Elhilali MM, Britton S, Brosman, S, Fahey JL (1976) Critical evaluation of lymphocyte functions in urological cancer patients. Cancer Res 36:132–137
Evans JT, Goldrosen MH, Han T, Minowada J, Howell J, Mittelman A, Ming Chu T, Holyoke ED (1977) Cell mediated immune status of colon cancer patients. Cancer 40:2516–2525
Gatti RA, Good RA (1971) Occurrence of malignancy in immunodeficiency disease. A literature review. Cancer 28:89–98
Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrica 52:203–223
Gil J, Orlowski T, Nowakowski W, Ko HL, Roszkowski K, Roszkowski W, Szmigielski S, Pulverer G, Jeljaszewicz J (1980) Local immunotherapy of stomach and intestinal carcinoma by Propionibacterium granulosum. Dis Colon Rectum 23:536–542
Golub SH, Forsythe AB, Morton DL (1977) Sequential examination of lymphocyte proliferation capacity in patients with malignant melanoma receiving BCG immunotherapy. Int J Cancer 19:18–26
Hoover R, Fraumens JF (1973) Risk of cancer in renal transplant recipients. Lancet II:55–58
Jerrells TR, Dean JH, Richardson G, Cannon GB, Herberman RB (1979) Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer. Int J Cancer 23:768–776
Jondal M, Holm G, Wigzell H (1972) Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming non-immune rosettes with sheep red blood cells. J Exp Med 136:207–215
Kopersztych S, Rezkallah MT, Miki SS (1976) Cell mediated immunity in patients with carcinoma: correlation between clinical stage and immunocompetence. Cancer 38:1149–1154
Kowalczyk D, Zembala M (1978) Migration inhibition of T lymphocytes from human peripheral blood by specific antigen and lymphokines. Clin Exp Immunol 32:333–338
Kowalczyk D, Zembala M, Popiela T, Łabza H (1978) The in vitro migration inhibition of mononuclear cells in patients with colorectal carcinoma. Arch Immunol Ther Exp (Warsz.) 26:435–439
Kowalczyk D, Zembala M, Ruggiero I (1985) Monocyte regulation of lymphokine production in cancer patients. J Clin Lab Immunol (in press)
Mantovani A, Tagliabue A, Dean JH, Jerrells TR, Herberman RB (1979) Cytolytic activity of human monocytes on transformed and untransformed human fibroblasts. Int J Cancer 23:28–31
Manual for Staging of Cancer (1977) American Joint Committe for Cancer Staging and End-Results Reporting. AJCCS, Chicago
Moertel CG, Ritts RE, O'Connell MJ, Silvers A (1979) Nonspecific immune determinants in patients with unresectable gastrointestinal carcinoma. Cancer 43:1483–1492
Mytar B, Zembala M, Uracz W, Czupryna A (1982) Cytostatic activity on tumour cells of monocytes from patients with gastrointestinal cancer. Cancer Immunol Immunother 130:190–193
Neilan BA (1980) Lack of correlation of T and B lymphocytes with stage of colorectal carcinoma. Dis Colon Rectum 23:65–67
O'Neill B Jr (1970) Monocytosis in malignant disease. Ann Int Med 73:991–992
Nordman E, Saarimaa H, Toivanen A (1978) The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients. Cancer 41:64–69
Nyholm RE, Currie GA (1978) Monocytes and macrophages in malignant melanoma. II. Lysis of antibody-coated human erythrocytes as an assay of monocyte function. Br J Cancer 37:337–344
den Oetter W, Dullens HFJ, de Weger RA (1983) Macrophages and antitumour reactions. Cancer Immunol Immunother 16:67–71
Oldham RK, Gail MH, Baker MA, Forbes JT, Heineman W, Hersh E, Holmes EC, Ritts RE, Wright PW and Lung Cancer Study Group (1982) Immunological studies in double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. Cancer Immunol Immunother 13:164–173
Olkowski ZL, McLaren JR, Skeen MJ (1978) Effects of combined immunotherapy with Levamisole and Bacillus Calmette-Guerin on immunocompetence of patients with squamous cell carcinoma of cervix, head and neck, and lung undergoing radiation therapy. Cancer Treat Rep 62:1651–1661
Popiela T, Zembala M, Oszacki J, Jedrychowski W (1982) A follow-up study on chemoimmunotherapy (5-Fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 13:182–184
Prehn RT (1971) Immunosurveillance, regeneration and oncogenesis. Prog Exp Tumor Res 14:1–11
Simo-Camps S, Anguera A, Ma Vich J, Vidal-Ribas A, Sala F, Sarrias R, Gumma J, Gri E, Ma Puigdollers J (1976) Immunological impairment in patients with non-lymphoid cancer. Cancer 37:724–728
Stein JA, Adler A, BenEfraim SH, Maor M (1976) Immunocompetence, immunosuppression and human breast cancer. I. An analysis of their relationship by known parameters of cell-mediated immunity in well defined clinical stages of disease. Cancer 38:1171–1187
Teasdale C, Hughes LE, Whitehead RH, Newcombe RG (1979) Factors effecting pretreatment immunocompetence in cancer patients. I. The effect of age, sex and ill health. II. The corrected effects of malignant disease. Cancer Immunol Immunother 6:89–99
Trejdosiewicz lk, Treydosiewicz AJ, Ling NR, Dykes PW (1979) Growth enhancing property of human monocytes from normal donors and cancer patients. Immunology 37:247–252
Unger SW, Bernhard MJ, Pace RC, Wanebo HJ (1983) Monocyte dysfunction in human cancer. Cancer 51:669–674
Uracz W, Pituch-Noworolska A, Zembala M, Popiela T, Czupryna A (1982a) “Activated” monocytes in gastric cancer patients. I. Increased Fc receptor expression, antibody-dependent cellular cytotoxicity and NBT reduction. J Cancer Res Clin Oncol 104:181–190
Uracz M, Mytar B, Zembala M, Ruggiero I, Popiela T, Czupryna A (1982b) “Activated” monocytes in gastric cancer patients. II. Suppressor and cytostatic activity in vitro. J Cancer Res Clin Oncol 104:307–313
Waldman RH, Ganguly R, Cusumano CL (1978) Spontaneous MIF secretion by peripheral lymphocytes of cancer patients. J RES 23:335–341
Wanebo HJ, Rao B, Attiyeh F, Pinsky C, Middleman P, Stearns M (1980) Immune reactivity in patients with colorectal cancer: Assessment of biologic risk by immune parameters. Cancer 45:1254–1263
West WH, Sienknecht CW, Townes AS, Herberman RB (1976) Performance of a rosette assay between lymphocyte and sheep erythrozyte at elevated temperatures to study patients with cancer and other diseases. Clin Immunol Immunopathol 5:60–66
Wybran J, Fudenberg HH (1973) Thymus derived rosette forming cells in various disease states: cancer, lymphoma, bacterial and viral infections and other diseases. J Clin Invest 52:1026–1032
Zembala M (1981) Tests for monocyte function in human disease. Clin Immunol Allergy 1:543–560
Zembala M, Mytar B, Ruggiero I, Uracz W, Popiela T, Czupryna A (1983) Suppressor cells and survival of patients with advanced gastric cancer. J Natl Cancer Inst 70:223–228
Zembala M, Uracz W, Ruggiero I, Mytar B, Pryjma J (1984) Isolation and functional characteristics of FcR+and FcR-human monocyte subsets. J Immunol 133:1293–1299
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zembala, M., Popiela, T., Kowalczyk, D. et al. Serial immunological testing in patients with gastric cancer. J Cancer Res Clin Oncol 111, 62–70 (1986). https://doi.org/10.1007/BF00402779
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00402779